



Entrez Gene

Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Be

Search

for

Go

Clear

☒ current records or

Limits

Preview/Index

History

Clipboard

Details

Entrez

Display

Graphics

Show:

Send to

Text

SITE MAP
Entrez HelpGene
Search
Gene Help


FAQ

Related sites
Entrez Genome
Genomic Biology
HomoloGene
LocusLink
Map Viewer
OMIM
RefSeq
UniGeneFeedback
Help Desk
Corrections
Submit GeneRIFsSubscriptions
RefSeq
Gene
Map Viewer**1: ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) [*Homo sapiens*]**

Links

GeneID: 2064 Locus tag: HGNC:3430

updated 05-Apr-2004

Transcripts and products: [RefSeq below](#)[NC_000017](#)**Genomic context:** chromosome: 17; Maps: 17q11.2-q12; 17q21.1**Gene type:** protein coding**Gene name:** ERBB2**Gene description:** v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)**RefSeq status:** Provisional**Organism:** *Homo sapiens***Lineage:** *Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo***Gene aliases:** NEU; NGL; HER2; TKR1; HER-2**General protein information:**

Names: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog

Avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog)

Bibliography:[PubMed links](#)**GeneRifs:**

1. ErbB1 and ErbB2 employ different mechanisms of plasma membrane targeting during keratinocyte differentiation, and that cytoskeletal association may facilitate the coupling of activated ErbB1 and ERK.
2. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the inhibitor geldanamycin (HSP90)
3. evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer; implications for daily laboratory practice
4. evaluation of relative prognostic weight in breast cancer using multivariate analysis

5. cells overexpress HER2. Signals from overexpressed EGFRs contribute to the constitutive phosphorylation of Erk, but these signals may not required for the constitutive activation of PI3K or AKT1.
6. ErbB2 can be a useful marker for tumour contamination in aphereses of patients affected by ErbB2-expressing osteosarcomas and that analysis of Bone Sialoprotein expression can be an alternative useful marker.
7. YAP is a potential signaling partner of the full-length ErbB4 receptor at the membrane and of the COOH-terminal fragment of ErbB-4 that translocates to the nucleus to regulate transcription
8. peptide library generation for HER2/neu ligand identification
9. HER-2 gene amplification and protein overexpression has been associated with increased risk of advanced-stage breast cancer and poor prognosis.
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
11. overexpression not associated with in vitro drug resistance to CMF or FEC chemotherapy combinations in primary breast cancer
12. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
13. Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells
14. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
15. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.
16. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma
17. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines
18. ErbB-2 demonstrates a strong tendency toward stable self-association of transmembrane domains identifiable as coexisting populations of peptides whose associations are thought to modulate signal transduction.
19. lack of amplification in nasopharyngeal neoplasms
20. feasibility of fluorescence in situ hybridization analysis of HER-2/neu amplification in oral mucosa brushings and to compare the HER-2/neu status with the history and smoking and drinking habits of healthy subjects
21. Data suggest that amplification of Her-2/neu appears to be mainly involved in initiation of breast oncogenesis and that its role in progression of breast cancers is uncertain.
22. Except in a certain subset of cases, aneusomy 17 probably is not a significant factor for HER-2/neu protein expression or for clinical assessment of HER-2/neu status.
23. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes
24. Increased c-erbB-2 expression contributes to the development of cholangiocarcinogenesis into an advanced stage associated with tumour metastasis.

25. expression of cyclooxygenase 2 in HE-2 positive breast cancer
26. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers
27. expression correlated with increased event-free and overall survival in high-grade osteosarcoma
28. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas.
29. p53 mutational pathway may favor selection for ErbB2 gene amplification during tumor progression in breast cancer
30. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta
31. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu are expressed in ovarian cancer.
32. gene is essential in preventing dilated cardiomyopathy
33. overexpression seen in 16% of NSCLC tumors, most frequently in adenocarcinomas and large cell carcinomas
34. identification of a dimerization motif for ErbB homomeric association
35. ErbB2 activation of ESX gene expression
36. ErbB2 membrane RTK can confer resistance to taxol-induced apoptosis by directly phosphorylating Cdc2.
37. HER-2/neu peptides can activate T cells in draining lymph nodes from women with invasive breast cancer.
38. S-erbB-2 serum levels above 40 U/ml independently predicted unfavorable response to 2d-line hormone or chemotherapy in advanced metastatic breast cancer. 1st-line drugs may select for overexpression of erbB-2 genes and lesser response to 2d-line drugs.
39. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression
40. Role of the N-terminus of epidermal growth factor in binding studied by phage display.
41. Her-2/neu expression and gene amplification in gastrinomas is correlated with tumor biology, growth, and aggressiveness.
42. Overexpression of erbb2 increases expression of VEGF A, C and D in breast carcinoma
43. the expression of mitochondria-encoded COXII is HRG-responsive. The levels of ErbB2 expression are decisive for the diverse biological activities of HRG.
44. ERBB2 binds to the SH2 domain of CHK and inhibits cell growth in human breast tumor cell lines
45. The expression of this molecule and its correlation with prognostic markers in patients with head and neck tumors
46. ErbB1 and ErbB2 employ different mechanisms of plasma membrane targeting during keratinocyte differentiation; cytoskeletal association may facilitate the coupling of activated ErbB1 and ERK.
47. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.

48. HER-2 tyrosine phosphorylation is a component of cytotoxic t-lymphocyte stimulation by tumor cells
49. overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin
50. uPA and its receptor are not upregulated by the circulating fraction of this proto-oncogene in advanced NSCLC
51. Data report the identification of signaling pathways required for suppression of integrin alpha2beta1 function by c-erbB2.
52. Overexpression of c-erbB-2 was significantly associated with poor survival & can serve as a prognostic marker. C-erbB-2 is related with tumor progression in colorectal cancer which can be seen on protein level & reflects chromosomal gain at the 17q locus.
53. Wound closure could be delayed up to 50% by antisense c-erbB2.
54. ILC did not display ERBB2 overexpression . The observed discrepancy in the pattern of the human oncogenes CCND1 and ERBB2, which are involved in the process of carcinogenesis of ductal tumors.
55. significant HER2 expression seen in high-grade, muscle-invasive urothelial carcinoma; but HER2 expression in context of paclitaxel-based chemotherapy associated with significantly reduced risk of death
56. Prognostic value of the quantitative measurement of the oncoprotein p185 (Her-2/neu) in a group of patients with breast cancer and positive node involvement.
57. HER2 expression is regulated by the interaction of DRIP130 and ESX
58. c-myc and c-erbB2 amplification in breast cancer
59. differential gene expression patterns in positive and negative breast cancer cell lines and tissues
60. High-level coexpression of ERBB2 and ERBB4 was significantly related to tumor proliferative activity in ependymoma
61. marked intratumoral heterogeneity of c-myc and cyclinD1 but not this gene in breast cancer
62. C-erb-2 overexpression is not statistically related to either proliferation or cancer specific death in upper urinary tract urothelial tumors.
63. contribution of HER2 transcription factor binding site to ERBB2 overexpression
64. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma.
65. Kaplan-Meier curves showed a significantly worse disease-related survival ($p = 0.034$) in patients with HER2-overexpressing tumors compared to those without HER2 overexpression.
66. Signaling by HER-2/neu has a critical role in the early stages of breast tumorigenesis.
67. relationship between the mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma
68. selective binding and sequestration of this residue in its unphosphorylated state by the Erbin PDZ provides a novel mechanism for regulation of the ErbB2-mediated signaling and oncogenicity
69. may be activated in the early stage of pathogenesis of cervical carcinoma in

geriatric patients

70. Computational exploration of conformation space of erbB2 homodimer transmembrane segments revealed 2 stable conformations: the active & inactive states of erbB2. Molecules may switch from one to the other without crossing unfavorable states.
71. Overexpressed erbB-2 can cause EGF independent transformation of nonmalignant MCF-10A breast cells.
72. Differential expression follows BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder
73. role of overexpression in lung cancer development in conjunction with erbB-3 overexpression
74. identification of domain motifs required for geldanamycin-induced degradation
75. Transcriptional analysis reveals a molecular connection to fatty acid synthesis.
76. up-regulates S100A4 and several other prometastatic genes in medulloblastoma
77. examination of amplification in breast cancer
78. reduced ER/PR expression may be one mechanism to explain the relative resistance of HER-2/neu-positive/HR-positive tumors to hormone therapy.
79. Her-2/neu overexpression in patients with osteosarcoma is associated with an increased risk of lung metastasis
80. UROC28 mRNA expression was greater in breast cancers than in noncancerous tissues ($p < 0.0001$), as was ERBB2 mRNA.
81. HER-2/neu overexpression does not adversely and may favorably influence response to adjuvant oophorectomy and tamoxifen treatment in patients with estrogen receptor-positive breast tumors
82. ErbB2 is a target of CHIP ubiquitin ligase activity; CHIP E3 controls both the association of Hsp70/Hsp90 chaperones with ErbB2 and the down-regulation of ErbB2 induced by inhibitors of Hsp90
83. Tumors expressing this protein produced more in the affected breast than in the unaffected breast in unilateral breast cancer.
84. results may suggest the contribution of c-erbB-1 molecule in progression of gastric carcinomas in southern Iranian patients
85. results demonstrate that tamoxifen resistant MCF-7 cell growth is mediated by the autocrine release and action of an epidermal growth factor receptor-specific ligand inducing preferential epidermal growth factor receptor/c-erbB2 dimerization
86. Inhibition of erbB receptor family members protects HaCaT keratinocytes from ultraviolet-B-induced apoptosis. This inhibition was specific for the erbB receptor family and specific for ultraviolet-B-induced apoptosis.
87. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
88. Crystal structures of the entire extracellular regions of rat HER2 at 2.4 Å and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 Å
89. model in which ErbB2 is already in the activated conformation and ready to

- interact with other ligand-activated ErbB receptors
90. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor; following a mechanical injury, heregulin-alpha activates erbB2 in cells at the edge of the wound, and this process hastens restoration of epithelial integrity
 91. erbB-2-mediated invasiveness is dependent on p38MAPK induces cell surface alpha4 integrin downregulation
 92. Expression of c-erbB-2 occurs more often in breast cancer cases than in cervical cancer and shows a significant relationship with histologic grading of the tumor, in a study group of Indian women.
 93. EGFR/HER2 heterodimers traffic as single entities; levels of HER2 in normal cells are barely at the threshold necessary to drive efficient heterodimerization
 94. our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt.
 95. HER2 expression together with PgR negativity may serve as the counterpart of the proliferation marker in predicting the in vivo response to DXR.
 96. This gene is amplified in breast cancer.
 97. ERBB-2 signaling is regulated by a MUC4/sialomucin complex
 98. results demonstrated significant positive staining of c-erbB-2 in the salivary tumorigenic tissue but not in the surrounding non-tumorigenic tissue, pointing to a biological role in the tumorigenic process
 99. Expression of epidermal growth factor receptor, erbB2, and erbB3, but not erbB4, was detected throughout the epidermis. Labeling for erbB2 and erbB3 accentuated in upper spinous layers
 100. in MCF-7 breast cancer cell line, elevated MAPK activity results from enhanced ERBB2 expression in the estrogen deprived cells
 101. MUC1 expression was inhibited by NGF treatment in breast cancer tumor cell lines, suggesting that its expression can be regulated by signals resulting from the homodimerization of Erb-B2.
 102. no evidence that the phosphorylation of TuM2-PK is initiated by the oncoprotein HER-2/neu in breast cancer patients
 103. Levels of this protein in blood are positive predictors of the treatment of breast cancers with herceptin.
 104. Levels of this receptor in blood serve as a predictive marker for the clinical course of breast cancer.
 105. Data support that EGFR and HER-2/neu play an important role in cell cycle control in ductal carcinoma in situ.
 106. Aberrations of these genes is regulated in tumor microenvironments.
 107. ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation.
 108. HER-2 expression and cell proliferation seem to provide prognostic information for node-negative breast cancer patients.
 109. overexpression of HER-2/neu gene could induce NF-kappaB activity in human breast cancer cells
 110. The presence of increased levels of HER2/neu in synovial sarcoma is associated with a more favorable clinical course.

111. The review evaluates the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.
112. ER81 is acetylated by two coactivators/acetyltransferases, p300 and p300- and CBP-associated factor (P/CAF) . Whereas p300 acetylates two lysine residues (K33 and K116) within the ER81 N-terminal transactivation domain, P/CAF targets only K116.
113. different transcriptional and post-transcriptional mechanisms are responsible for the increased levels of erbB-2 transcript and protein in breast and non-breast cancer cells
114. our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation.
115. overexpression of HER2/neu is associated with the development of muscle-invasive transitional cell carcinoma of the bladder
116. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer
117. HER2 has a role in reducing apoptosis in breast cancer cells treated with 4-HPR
118. data suggest that HER-2 amplifications are frequently linked to alterations of the TOP2A gene in bladder cancer
119. value of this tumor marker regarding relapse, metastasis and death in resectable non-small cell lung cancer
120. a detailed characterization of the molecular events occurring at the ERBB2 amplicon in primary breast tumors
121. This study highlights a new pathway by which HER-2 may modify cancer behaviour.
122. Immunization Her-2/neu peptides successfully induced humoral immune response with anti-tumor activity in an animal model of breast cancer.
123. HER2/neu disrupts cell-cycle regulation. (review)
124. Her2/neu contributes to the growth of some Wilms' tumors, and an important mechanism of its action is promotion of angiogenesis.
125. c-erbB-3 is overexpressed and amplified as a single and combined prognostic parameter in breast cancer.
126. HER-2/neu overexpression correlated with AKT activation (P=0.015).
127. There is a clear-cut difference in Her-2/neu amplification between screen-detected and interval breast carcinomas.
128. Study indicate that the coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
129. In Paget's disease of breast, ERBB-2 protein overexpression is caused by amplification of the ERBB2 gene. ERBB-2 protein overexpression is caused by amplification of the ERBB2 gene.
130. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of gastric tumor differentiation
131. ErbB2 receptor has a role in the inhibition of the IGF-I-induced Shc-MAPK

- signaling pathway in breast cancer cells
132. research suggests that E6/E7 cooperates with ErbB-2 in head and neck carcinogenesis, at least in part, via the conversion of beta-catenin from a cell adhesion to a nuclear function, that is, to act as a potential transcriptional regulator
 133. overexpression of ErbB2 enhanced NF-kappaB activation induced by ionizing radiation in human breast carcinoma MCF-7 cells transfected with ErbB2 genes (MCF-7/ErbB2)
 134. regulation by hereulin through heterodimer formation with ErbB3
 135. COX-2 up-regulates VEGF-C and promotes lymphangiogenesis in human lung adenocarcinoma via the EP(1)/Src/HER-2/Neu signaling pathway.

► General gene information

GeneOntology

Provided by [GOA](#)

Function

[ATP binding](#)

[ErbB-3 class receptor binding](#)

[epidermal growth factor receptor activity](#)

[non-membrane spanning protein tyrosine kinase activity](#)

[receptor activity](#)

[receptor signaling protein tyrosine kinase activity](#)

[transferase activity](#)

Process

[cell proliferation](#)

[protein amino acid phosphorylation](#)

[protein amino acid phosphorylation](#)

[transmembrane receptor protein tyrosine kinase signaling pathway](#)

[transmembrane receptor protein tyrosine kinase signaling pathway](#)

Component

[extracellular](#)

[integral to membrane](#)

[membrane](#)

Evidence

IEA

TAS [PubMed](#)

IEA

IDA [PubMed](#)

IEA

TAS [PubMed](#)

IEA

TAS [PubMed](#)

IEA [PubMed](#)

TAS [PubMed](#)

IDA [PubMed](#)

IEA [PubMed](#)

IDA [PubMed](#)

IEA

IEA

Homology:

Mouse

[ErbB2](#) 11 57.00 cM [ErbB2](#)

NP_004439: EC 2.7.1.112

Sequence Tagged Site (Markers)

[RH75810](#) (e-PCR)

[GDB:181407](#) (e-PCR)

► NCBI Reference Sequences (RefSeq)

mRNA Sequence [NM_004448](#)

Source Sequence [M11730](#)

Product [NP_004439](#) v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog

Domains

[pfam01030: Receptor L domain](#) score:218

[cd00192: Tyrosine kinase, catalytic domain](#) score:883

[pfam00757: Furin-like cysteine rich region](#) score:135

[KOG1025: Epidermal growth factor receptor EGFR and related tyrosine kinases \[Signal transduction mechanisms\]](#) score:4014

► Related Sequences

Nucleotide	Protein
Genomic AB025285	None
mRNA AB025286	None
mRNA AF177761	AAD56009

mRNA	M11730	AAA75493
mRNA	X03363	CAA27060
	None	P04626

► Additional Links[UniGene Hs.446352](#)[MIM 164870](#)

Display	Graphics	Show:	20	Send to	Text
---------	----------	-------	----	---------	------

[Restrictions on Use](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Apr 6 2004 10:25:18